UNMC joins 60-plus institutions in monkeypox treatment trial

LINCOLN, Neb. (KLKN) — The University of Nebraska Medical Center is joining more than 60 other institutions across the nation in a monkeypox treatment trial.

The Study of Tecovirimat for Human Monkeypox Virus (STOMP) is a phase three trial evaluating the safety and efficacy of the use of tecovirimat as a treatment for monkeypox. 

STOMP is being led by the AIDS Clinical Trials Group and aims to study a broad population of those with monkeypox.

The medicine has been approved by the Food and Drug Administration to treat smallpox, but its efficacy against monkeypox is unknown.

More than 500 adults with monkeypox will be studied, including people with severe diseases and women who are pregnant or breastfeeding.

Categories: Health, Nebraska News, News